AbClon Inc (KQ:174900) — Market Cap & Net Worth
Market Cap & Net Worth: AbClon Inc (174900)
AbClon Inc (KQ:174900) has a market capitalization of $296.40 Million (₩437.36 Billion) as of August 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #14829 globally and #460 in its home market, demonstrating a 11.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AbClon Inc's stock price ₩21950.00 by its total outstanding shares 19925510 (19.93 Million). See 174900 capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
AbClon Inc Market Cap History: 2017 to 2026
AbClon Inc's market capitalization history from 2017 to 2026. Data shows change from $887.16 Million to $296.40 Million (-1.89% CAGR).
Index Memberships
AbClon Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$206.59 Billion | 0.14% | #136 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$206.59 Billion | 0.14% | #136 of 1384 |
Weight: AbClon Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AbClon Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AbClon Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.12x
AbClon Inc's market cap is 0.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $887.16 Million | $3.53 Billion | -$1.48 Billion | 0.25x | N/A |
| 2018 | $548.91 Million | $3.92 Billion | -$842.70 Million | 0.14x | N/A |
| 2019 | $541.48 Million | $14.38 Billion | $2.57 Billion | 0.04x | 0.21x |
| 2020 | $492.87 Million | $2.77 Billion | -$6.44 Billion | 0.18x | N/A |
| 2021 | $239.01 Million | $3.02 Billion | -$10.24 Billion | 0.08x | N/A |
| 2022 | $172.84 Million | $3.41 Billion | -$9.25 Billion | 0.05x | N/A |
| 2023 | $200.12 Million | $2.88 Billion | -$12.90 Billion | 0.07x | N/A |
| 2024 | $190.67 Million | $2.34 Billion | -$16.30 Billion | 0.08x | N/A |
| 2025 | $573.89 Million | $4.71 Billion | -$17.91 Billion | 0.12x | N/A |
Competitor Companies of 174900 by Market Capitalization
Companies near AbClon Inc in the global market cap rankings as of August 5, 2026.
Key companies related to AbClon Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
AbClon Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, AbClon Inc's market cap moved from $887.16 Million to $ 296.40 Million, with a yearly change of -1.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩296.40 Million | -48.35% |
| 2025 | ₩573.89 Million | +200.99% |
| 2024 | ₩190.67 Million | -4.72% |
| 2023 | ₩200.12 Million | +15.78% |
| 2022 | ₩172.84 Million | -27.68% |
| 2021 | ₩239.01 Million | -51.51% |
| 2020 | ₩492.87 Million | -8.98% |
| 2019 | ₩541.48 Million | -1.35% |
| 2018 | ₩548.91 Million | -38.13% |
| 2017 | ₩887.16 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of AbClon Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $296.40 Million USD |
| MoneyControl | $296.40 Million USD |
| MarketWatch | $296.40 Million USD |
| marketcap.company | $296.40 Million USD |
| Reuters | $296.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AbClon Inc
AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is… Read more